Therapeutic effects of high-dose dexamethasone combined with thalidomide and bortezomib on renal function in patients newly diagnosed multiple myeloma
- Author:
- No author available
- Journal Title:
- Journal of Leukemia & Lymphoma
- Issue:
- 10
- DOI:
- 10.3760/cma.j.issn.1009-9921.2012.10.009
- Key Word:
- 多发性骨髓瘤;肾功能不全;地塞米松;沙利度胺;硼替佐米;Multiple myeloma;Renal insufficiency;Dexamethasone;Thalidomide;Bortezomib
Abstract： Objective To assess the efficacy of high dose dexamethasone combined with bortezomib and thalidomide in multiple myeloma (MM) patients with acute renal failure.Methods 23 newly diagoosed MM patients with acute renal failure were treated with high dose dexamethasone combined with bortezomib and thalidomide.Results Reversal of renal failure was documented in 58.3 ％ (7/12) of those severe renal failure patients and 81.8 ％ (9/11) of renal failure patients.Renal function was reversed in 69.5 ％ (16/23) of all patients.The total response rate for MM was 60.9 ％ (14/23).The median time to response was 2 (1-5) months. Overall survival (OS) at 3 years was 56.5 ％ and the median survival time was 34.4 months.Conclusion Renal failure was reversible in the majority of newly diagnosed MM patients treated with highdose dexamethasone containing regimens.The addition of novel agents thalidomide and (or) bortezomib is safe and induces a more rapid renal failure reversal compared with routine chemotherapy.
- [1]Gentile M,Ciolli,Morabito F.Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA.[J].2010,84(3).
- [2]Kyle RA,Gertz MA,Witzig TE,etc.Review of 1027 patients with newly diagnosed multiple myeloma.[J].2003,78(1).
- [3]Dimopoulos MA,Richardson PG,Schlag.VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA study.[J].2009,27(36).
- [4]主编张之南, 李家增.血液病治疗学[M].2005.
- [5]张之南.血液病诊断及疗效标准[M].1998.
- [6]Magen Nativ H,Blade J,Dimopoulos M,etc.Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.[J].2011,16(4).
- [7]Kastritis E,Gavriatopoulou M,Dimopoulos MA,etc.Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents.[J].2010,34(10).
- [8]Ludwig H,Adam Z,Hajek R,etc.Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.[J].2010,28(30).
- [9]Adams J.Proteasome inhibition in cancer: development of PS-341.[J].2001,28(6).
- [10]Raab MS,Podar K,Breitkreutz I.Multiple myeloma.[J].2009,374(9686).
- [11]Hideshima T,Ikeda H,Chauhan D.Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.[J].2009,114(5).
- [12]Eda H,Aoki K,Kato S,etc.The proteasome inhibitor bortezomib inhibits FGF-2-induced reduction of TAZ levels in osteoblast-like cells.[J].2010,85(1).
- [13]Heher EC,Richardson PG,Raje NS,etc.Kidney disease associated with plasma cell dyscrasias.[J].2010,116(9).